NTRB News and Press, Nutriband Inc. From 09/03/25

2025-09-03 16:11:25 ET More on Nutriband Nutriband issued U.S. patent for transdermal abuse deterrent technology Seeking Alpha’s Quant Rating on Nutriband Historical earnings data for Nutriband Financial information for Nutriband Read the ful...

ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it has seen warrants exercised at a strike price of $6.43 for proceeds to the company of $5,306,000. ...

IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of) (IRS) is expected to report for quarter end 2025-06-30 Psychemedics Corporation (PMDI) is expected to report for quarter end 2025-06-30 FST Corp. (KBSX) is expected to report for quarter en...

Nutriband Inc. (NTRB) is expected to report $-0.17 for Q2 2026

2025-08-11 09:25:00 ET Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will step aside for three months to pursue candidacy in the Irish Presidential election, with nomination hearings and voting taking place in September and October. Co-Founder and Chairman Serguei Melnik, ...

Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election. Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and election period. ORLANDO, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NA...

2025-08-08 09:35:00 ET Nutriband (NASDAQ: NTRB) , a developer of prescription transdermal pharmaceutical products, announced the U.S. Food and Drug Administration has granted a Type C Meeting on Sept. 18, 2025, to review Chemistry, Manufacturing, and Controls plans for its lead product,...

FDA grants meeting for AVERSA™ FENTANYL (abuse deterrent transdermal system) to provide feedback on the Chemistry, Manufacturing, and Controls plans for the product through commercialization. Nutriband is partnering with Kindeva to develop AVERSA™ FENTANYL which combines Nut...

2025-08-06 10:55:00 ET Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversio...

2025-08-05 09:05:00 ET FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement CEO notes that “core goal is to contin...